Relief from Wall Street was obvious, with shares of South San Francisco-based Theravance (NASDAQ:THRX) jumping 21 percent, or $4.88, to close Monday at $28.63

San Francisco) and Dako (Glostrup, Denmark) Kadcyla Ado-trastuzumab emtansine HER2-positive metastatic breast cancer FDA approved its addition to the labeling of two Dako companion diagnostic assays 3/6/13 Navidea Biopharma-ceuticals Inc. (Dublin, Ohio) Lymphoseek Technetium Tc 99 m tilmanocept injection...San Francisco) Probuphine An implantable device delivering a steady dose of buprenorphine Opioid dependence FDA committee voted in favor of approval 10-4, with one abstention 3/22/13 INFECTION

San Francisco) and Bayer HealthCare (Wayne, N.J.) Stivarga Regorafenib Metastatic colorectal cancer Gained approval in Japan 3/27/13 PrimaBioMed Ltd. (Sydney, Australia) CVac Vaccine Ovarian cancer Started recruiting patients in a Phase II/III trial in Europe 3/1/13 Symbio Pharmaceuticals Ltd. (Tokyo) Rigosertib Small-molecule P13-kinase and PLK inhibitor Myelodysplastic syndromes Started enrolling patients in its Japanese Phase I trial 3/27/13 CARDIOVASCULAR Gentium SpA (Villa Guardia, Italy

GS-7977 Hepatitis C virus Clinical data showed 6 of 27 patients in the 12-week arm receiving simeprevir, sofosbuvir and ribavirin achieved SVR at week 4, while 13 of 14 patients in the 12-week arm receiving simeprevir and sofosbuvir without ribavirin achieved SVR4 3/7/13 Presidio Pharmaceuticals Inc. (San Francisco) and Boehringer Ingelheim GmbH (Ingelheim, Germany) PPI-668 Pan-genotypic HCV NS5A inhibitor Hepatitis C virus Plans to start a 12-week Phase IIa trial in the second quarter 3/14/13

The Genome Institute of Singapore and Fluidigm Corp., of South San Francisco, opened a new research center in Singapore, the Single-Cell Omics Centre

Most active pharma companies were Sanofi SA with five deals signed including Sanofi Pasteur, its vaccines division collaborating with Sutro Biopharma Inc., of San Francisco, to produce two undisclosed vaccine candidates

OxiGene Inc., of South San Francisco, entered agreements with institutional investors for a private placement of $5 million of zero coupon convertible preferred stock, convertible into approximately 1.38 million shares of common stock at a price of $3.63 apiece, and two series of warrants that may be exercised for up to approximately 2.76 million additional shares of common stock at a price of $3.40 apiece

Oxigene Inc., of South San Francisco, received U.S. Patent No

Exelixis Inc., of South San Francisco, presented additional information about the mechanism of action of cabozantinib with respect to activity against prostate cancer tumors metastasized to bone

VistaGen Therapeutics Inc., of South San Francisco, will receive a $36 million investment from Bergamo Acquisition Corp

Jennerex Biotherapeutics Inc., of San Francisco, presented research demonstrating the antivascular effect of lead candidate Pexa-Vec (JX-594, pexastimogene devacirepvec), an investigational oncolytic immunotherapy

Cleave Biosciences Inc., of San Francisco, raised $10 million in an extension of its Series A financing from new investor New Enterprise Associates (NEA), bringing its Series A total to $54 million

Nektar Therapeutics Inc., of San Francisco, presented preclinical data showing that cancer immunotherapeutic NKTR-214 targets the IL-2 receptor complex through selective receptor binding to the IL2Rβ subtype, activating destruction of the tumor by the body's immune system

Nektar Therapeutics Inc., of San Francisco, presented preclinical data showing that cancer immunotherapeutic NKTR-214 targets the IL-2 receptor complex through selective receptor binding to the IL2Rβ subtype, activating destruction of the tumor by the body's immune system

C$7.3 ($7.14) N/A Hyperion Therapeutics Inc. (South San Francisco; HPTX)5 3/8/13 3/8/13 3.23S $20.75 19.95 Leerink Swann Cowen & Co. (co-lead) Needham & Co...Brean Capital Maxim Group LLC $15.06 $98.945 Medgenics Inc. (San Francisco; MDGN)7 10/26/12 3/26/13 6.07S and Series 2013-A W for 3.22S $5.25 18.37 Maxim Group LLC National Securities Corp

With the close of the financing, San Francisco-based Labrys acquired global rights to RN-307 a Phase II-ready anti-calcitonin gene-related peptide (CGRP) humanized monoclonal antibody (MAb) from Pfizer Inc...RN-307 was discovered and originally developed by Rinat Neuroscience Corp., a South San Francisco protein therapeutics company that was acquired by Pfizer in 2006. (See BioWorld Today, April 10, 2006.) In a Series C financing Versartis Inc., of Redwood City, Calif., raised $25 million to

In January, for example, Onyx Pharmaceuticals Inc., of South San Francisco, padded its bank balance with $358.6 million following a public offering of 4.4 million shares

In January, for example, Onyx Pharmaceuticals Inc., of South San Francisco, padded its bank balance with $358.6 million following a public offering of 4.4 million shares

Raul Rodriguez, chief operating officer of South San Francisco-based Rigel, pointed out that the ACR20 score before placebo adjustment was 49 percent, "which isn't that different from